Rxcrossroads 3PL Llc

Rxcrossroads 3PL LLC is a third-party logistics (3PL) provider specializing in the importation and distribution of pharmaceutical products within the United States. Established in 2019, the company is headquartered at 4200 Binion Way, Suite 200, Mason, Ohio 45036. The Managing Member is Michele Lau, who can be contacted at (866) 447-9758.

As a 3PL, Rxcrossroads 3PL LLC plays a pivotal role in the U.S. pharmaceutical supply chain by facilitating the importation, storage, and distribution of pharmaceutical formulations sourced from international suppliers, particularly India. The company's operations encompass a range of services, including warehousing, inventory management, and logistics coordination, ensuring the efficient delivery of pharmaceutical products to various stakeholders within the healthcare sector.

Rxcrossroads 3PL LLC operates multiple facilities across the United States to support its distribution network. Notable locations include:

• Mason, Ohio: The primary headquarters situated at 4200 Binion Way, Suite 200, Mason, Ohio 45036.

• Fairdale, Kentucky: A branch located at 1001 Cheri Way, Fairdale, Kentucky 40118.

• Erlanger, Kentucky: Another branch situated at 2801 Crescent Springs Pike, Erlanger, Kentucky 41018.

These strategically positioned facilities enable Rxcrossroads 3PL LLC to effectively manage its logistics operations, ensuring timely and reliable distribution of pharmaceutical products across the United States.

In the U.S. pharmaceutical supply chain, Rxcrossroads 3PL LLC functions as a logistics intermediary. By importing pharmaceutical formulations from international suppliers, particularly India, the company bridges the gap between foreign manufacturers and the U.S. market. This role is crucial in ensuring a steady supply of pharmaceutical products, especially generics, to meet the demands of healthcare providers and patients.

Rxcrossroads 3PL LLC demonstrates a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from India. The company's total import value from India amounts to $6.4 million USD, encompassing 141 shipments and 242 unique formulations across six products and five therapeutic categories. This concentration indicates a strategic choice to leverage India's robust pharmaceutical manufacturing capabilities, particularly in the production of generic medications.

The shipment data reveals a stable relationship with key Indian suppliers, including Unichem Laboratories Limited, Wintac Limited, and Torrent Pharmaceuticals Limited. The substantial number of shipments from these suppliers suggests a well-established and reliable supply chain. However, the high concentration also presents a potential risk; any disruptions in India's pharmaceutical manufacturing or export processes could impact Rxcrossroads 3PL LLC's ability to meet U.S. market demands.

Rxcrossroads 3PL LLC's supply chain resilience is closely tied to its reliance on Indian pharmaceutical manufacturers. The company's import portfolio includes 242 unique formulations, indicating a diverse range of products sourced from India. This diversity can mitigate risks associated with dependency on a single product line.

However, the supply chain's resilience is contingent upon the stability of Indian suppliers and the efficiency of shipping routes. Disruptions in India's manufacturing sector, such as regulatory changes or logistical challenges, could affect the timely delivery of products. Additionally, compliance with U.S. Food and Drug Administration (FDA) regulations is essential to ensure the quality and safety of imported pharmaceutical products.

Rxcrossroads 3PL LLC's sourcing pattern positions it as a key player in the U.S. pharmaceutical market, particularly in the generic drug segment. The company's focus on importing a diverse array of formulations from India allows it to offer a wide range of products to meet various therapeutic needs.

For Indian pharmaceutical exporters, this presents an opportunity to establish or strengthen partnerships with Rxcrossroads 3PL LLC. By ensuring compliance with FDA regulations and maintaining high-quality standards, Indian suppliers can position themselves as reliable partners in Rxcrossroads 3PL LLC's supply chain, thereby expanding their reach in the U.S. market.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces regulations to ensure that imported drugs meet U.S. standards for safety, efficacy, and quality.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines the requirements for drug approval, labeling, and manufacturing practices. Additionally, the Drug Enforcement Administration (DEA) regulates controlled substances, ensuring that imports comply with the Controlled Substances Act.

Import licensing requirements for pharmaceutical products entering the U.S. are stringent. Importers must register with the FDA and obtain an Importer of Record number. Each imported drug must be accompanied by a valid New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) approval.

Good Manufacturing Practice (GMP) certification is crucial for ensuring the quality of pharmaceutical products. The FDA recognizes GMP certifications from the European Union (EU GMP), World Health Organization (WHO GMP), and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must verify that their foreign suppliers hold valid GMP certifications from recognized authorities to ensure compliance with U.S. standards.

Imported pharmaceutical products must undergo batch testing to confirm their identity, strength, quality, and purity. This testing ensures that the products meet the specifications outlined in their approved applications.

Stability requirements mandate that drugs maintain their intended quality over a specified shelf life. Labeling must include information such as the drug's name, dosage form, strength, directions for use, and storage conditions. In the U.S., labeling must be in English and comply with FDA regulations.

Serialization mandates require that each saleable unit of a prescription drug be assigned a unique serial number. This system enhances traceability and helps prevent counterfeit drugs from entering the supply chain.

Between 2024 and 2026, the FDA implemented several policy changes affecting pharmaceutical imports from India. These changes include stricter enforcement of GMP compliance, enhanced scrutiny of drug labeling and packaging, and increased inspections of foreign manufacturing facilities. Importers must stay informed about these regulatory updates to ensure continued compliance and avoid potential disruptions in their supply chains.

Rxcrossroads 3PL LLC's focus on importing pharmaceutical formulations in the analgesics and antipyretics, respiratory and over-the-counter (OTC), and oncology therapeutic categories aligns with market demand for these essential medications. The substantial import value of tramadol, ephedrine, and doxorubicin indicates a strategic emphasis on pain management, respiratory treatments, and cancer therapies.

Market demand for these products is driven by the prevalence of chronic pain conditions, respiratory diseases, and cancer, necessitating a consistent supply of effective treatments. By concentrating on these therapeutic areas, Rxcrossroads 3PL LLC positions itself to meet critical healthcare needs within the U.S. market.

Rxcrossroads 3PL LLC's sourcing strategy centers on importing generic pharmaceutical formulations from India. The company's portfolio includes a diverse range of products across multiple therapeutic categories, indicating a preference for a broad selection of formulations to cater to various patient needs.

India's established pharmaceutical manufacturing sector, recognized for its compliance with international GMP standards, makes it a strategic partner for sourcing high-quality generic drugs. Rxcrossroads 3PL LLC's sourcing profile reflects a commitment to providing cost-effective and reliable pharmaceutical products to the U.S. market.

Based on its product mix, Rxcrossroads 3PL LLC serves multiple segments of the U.S. pharmaceutical market. The company's focus on analgesics, respiratory treatments, and oncology medications positions it to supply retail pharmacies, hospitals, and healthcare providers with essential drugs. Additionally, the company's role as a logistics intermediary enables it to support wholesale distribution channels, ensuring a steady supply of pharmaceutical products across the healthcare system.

There is a realistic opportunity for new Indian suppliers to partner with Rxcrossroads 3PL LLC. The company's substantial import volume and diverse product portfolio indicate a continuous need for reliable suppliers to meet the demands of the U.S. market.

Gaps in Rxcrossroads 3PL LLC's current sourcing may exist in specific therapeutic areas or product formulations. Indian exporters can explore these opportunities by